Research Topics
| R B WomerSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in childrenR B Womer
Division of Oncology, Children s Hospital of Philadelphia, PA 19104, USA
Eur J Cancer 36:87-94. 2000..G-CSF permits intensification of this regimen through interval compression. The impact of this approach on efficacy remains to be determined in a randomised trial...- Multidisciplinary systems approach to chemotherapy safety: rebuilding processes and holding the gainsRichard B Womer
Department of Pediatrics and School of Nursing, University of Pennsylvania, PA, USA
J Clin Oncol 20:4705-12. 2002..We have undertaken a thorough revision of our systems for inpatient chemotherapy... - Rhabdomyosarcoma and soft tissue sarcoma in childhoodR B Womer
Department of Pediatrics, The Children s Hospital of Philadelphia and University of Pennsylvania, 19104, USA
Curr Opin Oncol 12:337-44. 2000..Our understanding of the natural history of nonrhabdo soft tissue sarcomas in children has increased, and molecular diagnosis is becoming established. The role of chemotherapy in treatment remains controversial... - Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseY Li
The Center for Outcomes Research, The Children s Hospital of Philadelphia, 3535 Market St Suite 1029 Philadelphia, PA 19104, USA
Eur J Cancer 40:2445-51. 2004..48-180.94). Age at treatment and the cumulative dose of cisplatin were the two most important risk factors in predicting moderate to severe high-frequency hearing loss in children treated with cisplatin... - Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomasChanghu Chen
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 55:1294-9. 2003..To assess the influence of radiation volume on outcome in pediatric parameningeal rhabdomyosarcomas (PM-RMSs)... - Molecular diagnosis of ewing family tumors: too many fusions... ?Frederic G Barr
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 505C Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104-6100, USA
J Mol Diagn 9:437-40. 2007 - Long-term follow-up and prognosis of orbital apex syndrome resulting from nasopharyngeal rhabdomyosarcomaKenneth S Shindler
Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia 19104, USA
Am J Ophthalmol 140:236-41. 2005..The prognosis for recovery of vision and ocular motility in patients with an orbital apex syndrome due to nasopharyngeal rhabdomyosarcoma is examined... - Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupAlexander J Chou
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 115:5339-48. 2009..The authors report the results of addition of liposomal MTP-PE to chemotherapy for patients with metastatic OS... - Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusionsM H Collins
Department of Pathology, Children s Hospital of Philadelphia, Philadelphia, PA, USA
Med Pediatr Oncol 37:83-9. 2001.... - Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study GroupD O Walterhouse
Department of Pediatrics, Children s Memorial Hospital, Chicago, Illinois 60614, USA
Cancer 92:3135-46. 2001..Therefore, the authors reviewed the files of all patients with RMS of the parotid region who were registered on the Intergroup Rhabdomyosarcoma Studies (IRS) I-IV... - Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group studyNeyssa Marina
Department of Pediatrics, Stanford University Medical Center, Stanford, CA 94304, USA
Cancer 104:841-7. 2005..Amifostine appears to protect against toxicity. The authors combined amifostine with HDPEB and evaluated the efficacy and toxicity, specifically whether ototoxicity decreased... - Evolution of a Rapid Hydration ProtocolEllen Tracy
Children s Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104, USA
J Pediatr Oncol Nurs 21:22-6. 2004..Nurses developed and tested this innovative hydration strategy, which continues to be very effective... - Preventing organ-specific chemotherapy toxicityJill P Ginsberg
The Division of Oncology, Department of Paediatrics, The Children's Hospital of Philadelphia, The University of Pennsylvania School of Medicine, 34th Street and Civic Center Blvd, Philadelphia, PA 19104, USA
Eur J Cancer 41:2690-700. 2005..Clinical and bench research are necessary to develop interventions that will avoid or mitigate late effects and improve the health of pediatric cancer survivors... - Ewing's sarcomaNaomi J Balamuth
Division of Oncology, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Lancet Oncol 11:184-92. 2010..With many new approaches and relatively few patients, it will be challenging to integrate new and established treatments through clinical trials... - Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup studyNeyssa Marina
Stanford University Medical Center, Stanford, CA 94304 1812, USA
J Clin Oncol 24:2544-8. 2006..To investigate prognostic factors for pediatric extragonadal malignant germ cell tumors (PEMGCT)... - Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology GroupPaul A Meyers
Children s Oncology Group, Arcadia, CA, USA
J Clin Oncol 26:633-8. 2008..To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma... - Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study GroupK Scott Baker
University of Minnesota, Minneapolis, MN, USA
J Clin Oncol 20:4428-33. 2002..To define the clinical characteristics of rhabdomyosarcoma (RMS) occurring in children from ethnic minorities and determine whether these children have benefited equally from advances in therapy... - Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastomaMarcio H Malogolowkin
Childrens Hospital Los Angeles, Division of Hematology Oncology, Los Angeles, CA 90027, USA
J Clin Oncol 24:2879-84. 2006..The P9645 study was designed to compare the risk of treatment failure for patients with stage III/IV hepatoblastoma randomized to either C5V or CC... - Bladder/prostate rhabdomyosarcoma: miles to go before we sleepRichard B Womer
J Urol 176:1278-9. 2006 - Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapyRobert C Shamberger
Department of Surgery, Children s Hospital Boston, MA 02115, USA
Ann Surg 238:563-7; discussion 567-8. 2003..To establish outcome and optimal timing of local control for patients with nonmetastatic Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) of the chest wall...